What Moved Alnylam Stock? Trefis Team Thu, November 12, 2026 at 10:13 AM EST 3 min read ALNY -0.92% ^GSPC -0.15% CRWV -6.62% IONS -2.67% VRTX +0.28% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
For questions about this article or underlying research, email help@trefis.com.
Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Wednesday, November 11, 2026, while the S&P 500 gained 1.3%. The company did not report earnings around the move, and the median biotechnology company worth $2 billion or more rose 0.5%. So what else was going on for Alnylam that Wednesday?
Alnylam Rose From Its Year Low As Stocks Climbed
The wider market was rising. U.S. stocks gained that day after a CoreWeave earnings update eased worries that artificial-intelligence profits would not arrive soon enough to cover infrastructure debt.
Alnylam came into that session at its lowest close of the past year, $151.64 on November 10, after a 3.2% fall that day. Earlier, on October 29, the stock fell 25.1%, the day the company held its third-quarter earnings call.
Management said on that call it was "not yet satisfied with the underlying demand growth" it had seen. It also said it expected 2026 sales of its TTR drugs, which include AMVUTTRA, to land at the low end of its $4.2 billion to $4.5 billion range. Wednesday's gain started from that low point on a day the broad market went up.
Did Alnylam Rise With Other Biotech Stocks?
Most biotech stocks rose as well, but by much smaller margins. Of the 81 other biotechnology companies of that size, 50 recorded gains, yet just 4 added 5% or more as Alnylam did. Health care as a whole went nowhere, with the sector fund XLV finishing flat for the session.
Among Alnylam's Trefis peers, Regeneron Pharmaceuticals climbed 4.7%, while Gilead Sciences fell 0.7%. Alnylam rose far more than its sub-industry and its sector, though Regeneron came close.
Where Does Alnylam Stock Stand After The Gain?
A rise like this has happened before for Alnylam: the stock rose at least as much on 5 sessions in the past year. Counting falls too, it moved this much on 15 sessions, the latest being the October 29 drop.
The gain does little against the past twelve months, a period when the stock lost 63.8% while the S&P 500 returned 12.8%. Alnylam still sits far below its one-year high close of $473.29, set on December 3, 2025. The decline has been steep lately, bringing a 45.2% loss over six months and a 28.6% drop over the past month alone.
At the latest close, shares trade at 4.3 times Alnylam's trailing twelve-month sales, compared with 3.2 times for the S&P 500.
Alnylam is expected to report its fourth-quarter 2026 results in February 2027, when management plans to issue its 2027 product revenue guidance. Sales of its TTR drugs are the figure to watch in that report.
Does This Mean You Should Act On ALNY?
Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.
Spot an error or want more like this? Tell us in 10 seconds.
